Table 1.

The current mouse model used to study CDDP-AKI does not recapitulate the dosing regimen humans receive

Mouse dosing regimen of CDDP used to study AKI	Human dosing regimen of CDDP used to treat cancer
Mice receive 1 high dose of CDDP (10–30 mg/kg)	Humans receive low doses of cisplatin over a span of weeks/months
Mice die 3–4 days after CDDP treatment; long-term studies of kidney function cannot be performed	Goal of cisplatin treatment is to cure cancer without developing AKI, improve patient longevity
Mice used do not have cancer	Only patients with cancer receive cisplatin treatment
Mice used are usually young (8–10 wk of age)	The median age for all cancer diagnoses is 65

CDDP-AKI, cisplatin-induced acute kidney injury. The mouse model of CDDP-AKI consists of 1 high dose of cisplatin that causes mice to become moribund 3–4 days after treatment. In addition, mice used with this model are usually young and do not have cancer. To improve clinical relevancy, these limitations must be addressed.